Literature DB >> 15746633

Beneficial effect of aspirin on renal function in patients with renal insufficiency postcardiac surgery.

R Gerrah1, S Ehrlich, S Tshori, G Sahar.   

Abstract

AIM: Renal function is one of the most important prognostic factors following cardiac surgery. Whether aspirin affects cardiopulmonary bypass related renal injury is investigated in this study.
METHODS: Ninety-four patients with impaired renal function (creatinine = or >1.5 mg/dl) undergoing coronary artery bypass grafting (CABG) were categorized into 2 groups according to aspirin administration before surgery. Serum creatinine, urinary output and creatinine clearance along with other perioperative factors were compared between the 2 groups prior to surgery, 24 hours and 48 hours following cardiopulmonary bypass.
RESULTS: Creatinine levels increased significantly in the second postoperative day only in the non-aspirin (control) group (3.7+/-1.6 vs 2.9+/-1.7 mg/dl, p=0.03). Aspirin (study) group had lower creatinine levels in day 1 (p=0.03) and day 2 (p=0.001). Furthermore, in the study group creatinine clearance was higher in day 1 (34.3+/-14.3 vs 30.9+/-13.1 ml/min, p=0.01) and in day 2 (32.6+/-13.8 vs 26.4+/-9.8 ml, p<0.0001). Creatinine levels at discharge were elevated compared to the preoperative levels in the control group (p=0.01). However, the study group had lower creatinine levels at discharge (2.6+/-1.4 vs 3.8+/-1.6 mg/dl, p<0.0001). Urinary output was higher in the study group in the first postoperative day compared to the control group (p=0.01). Postoperative bleeding was slightly increased in the study group compared to the control group (760+/-230 ml vs 530+/-210 ml, p=0.01).
CONCLUSIONS: Continuation of aspirin administration until the day of surgery may have a protective effect against renal injury resulting from cardiopulmonary bypass, with only a negligible increase in bleeding. Possible explanations for this effect are antiplatelet activity of aspirin during cardiopulmonary bypass causing inhibition of vasoconstrictive agents like thromboxane, and improvement of renal perfusion by reducing blood viscosity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15746633

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  7 in total

Review 1.  Aspirin Use Prior to Coronary Artery Bypass Grafting Surgery: a Systematic Review.

Authors:  Ayman Elbadawi; Marwan Saad; Ramez Nairooz
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

Review 2.  Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review.

Authors:  Meyeon Park; Steven G Coca; Sagar U Nigwekar; Amit X Garg; Susan Garwood; Chirag R Parikh
Journal:  Am J Nephrol       Date:  2010-04-06       Impact factor: 3.754

3.  Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery.

Authors:  Miklos D Kertai; Shan Zhou; Jörn A Karhausen; Mary Cooter; Edmund Jooste; Yi-Ju Li; William D White; Solomon Aronson; Mihai V Podgoreanu; Jeffrey Gaca; Ian J Welsby; Jerrold H Levy; Mark Stafford-Smith; Joseph P Mathew; Manuel L Fontes
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

4.  Effects of preoperative aspirin on cardiocerebral and renal complications in non-emergent cardiac surgery patients: a sub-group and cohort study.

Authors:  Longhui Cao; Scott Silvestry; Ning Zhao; James Diehl; Jianzhong Sun
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

5.  Whole blood viscosity assessment issues V: Prevalence in hypercreatinaemia, hyperglycaemia and hyperlipidaemia.

Authors:  Ezekiel Uba Nwose
Journal:  N Am J Med Sci       Date:  2010-09

6.  Aspirin and clonidine in non-cardiac surgery: acute kidney injury substudy protocol of the Perioperative Ischaemic Evaluation (POISE) 2 randomised controlled trial.

Authors:  Amit X Garg; Andrea Kurz; Daniel I Sessler; Meaghan Cuerden; Andrea Robinson; Marko Mrkobrada; Chirag Parikh; Richard Mizera; Philip M Jones; Maria Tiboni; Raul Gonzalez Rodriguez; Ekaterina Popova; Maria Fernanda Rojas Gomez; Christian S Meyhoff; Tomas Vanhelder; Matthew T V Chan; David Torres; Joel Parlow; Miriam de Nadal Clanchet; Mohammed Amir; Seyed Javad Bidgoli; Laura Pasin; Kristian Martinsen; German Malaga; Paul Myles; Rey Acedillo; Pavel Roshanov; Michael Walsh; George Dresser; Priya Kumar; Edith Fleischmann; Juan Carlos Villar; Tom Painter; Bruce Biccard; Sergio Bergese; Sadeesh Srinathan; Juan P Cata; Vincent Chan; Bhupendra Mehra; Kate Leslie; Richard Whitlock; P J Devereaux
Journal:  BMJ Open       Date:  2014-02-25       Impact factor: 2.692

7.  Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.

Authors:  Jiang-Hua Ding; Li-Ya Yuan; Guo-An Chen
Journal:  Oncol Lett       Date:  2016-12-08       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.